Research programme: RNA-based tuberculosis therapies - Sarepta Therapeutics/Karolinska InstitutetAlternative Names: Bacterial PPMO for TB - Sarepta Therapeutics
Latest Information Update: 16 Jul 2012
At a glance
- Originator AVI BioPharma; Karolinska Institute
- Developer Karolinska Institute; Sarepta Therapeutics
- Class RNA
- Mechanism of Action Gene expression modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Tuberculosis